Drug Type Small molecule drug |
Synonyms 4,17beta-Dihydroxy-4-androstene-3-one, 4-Androstene-7alpha-17beta-diol-3-one, 4-hydroxy-testosterone + [6] |
Target |
Mechanism AR agonists(Androgen Receptor agonists), ERβ modulators(Estrogen receptor beta modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H28O3 |
InChIKeyBQOIJSIMMIDHMO-FBPKJDBXSA-N |
CAS Registry2141-17-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | 4-Hydroxytestosterone | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally advanced breast cancer | Phase 2 | CH | 14 Jun 2016 | |
Metastatic breast cancer | Phase 2 | CH | 14 Jun 2016 | |
Breast Cancer | Phase 2 | - | - |
Not Applicable | - | ynxdjlewvi(edzoabzmwz) = gdjatmqzxf opyhekzvdt (aofthzwgna, 24.6 - 49.1) | - | 11 Apr 2023 | |||
ynxdjlewvi(edzoabzmwz) = kcbkhvzuwu opyhekzvdt (aofthzwgna, 3.3 - 28.6) |